C. Garzoni

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.

Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2

The paper identifies broadly cross-reactive neutralizing antibodies against SARS-CoV-2 variants using coldspot-guided antibody discovery.

Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape

The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.

Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course

The paper finds that anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease outcomes and predict absence of long COVID symptoms.

ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.

Excessive inflammatory and metabolic responses to acute SARS-CoV-2 infection are associated with a distinct gut microbiota composition

This study identifies distinct gut microbiota compositions and metabolic/cytokine profiles associated with severe outcomes in SARS-CoV-2 infection.

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429

This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.

Clonal dissection of immunodominance and cross-reactivity of the CD4+ T cell response to SARS-CoV-2

The paper identifies immunodominant and cross-reactive CD4+ T cell epitopes in SARS-CoV-2, showing their recognition in 93% of patients and potential for vaccine design.

The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity

The paper shows the N439K SARS-CoV-2 spike variant maintains replication fitness while evading antibody neutralization.